Surgery

Funds from the Inasmuch Foundation and The Samuel Roberts Noble Foundation will support the purchase of equipment, including computerized eye simulators, a laser injector, and a device for measuring the electrical resistance of cells.

Dr. Frenkel highlights a comprehensive program that covers the latest breakthroughs in glaucoma and cataract surgery to in-depth discussions on AI, retinal treatments, and new drug-delivery platforms, all set against the backdrop of Snowmass, Colorado.

Wendy Lee, MD, an oculoplastics specialist and member of the program committee at EnVision Summit, shares an agenda that will include a mix of functional oculoplastics, aesthetics, and live facial rejuvenation demonstrations at the upcoming event, which will be held from February 14 to 17, 2025, at the Caribe Hilton San Juan in Puerto Rico.

Glaucoma specialists discuss pairing patients with the right procedures.

A Helsinki University Hospital study found diabetes, glycemic control, or insulin therapy did not significantly affect anatomical or functional outcomes after epiretinal membrane surgery.

The 14th annual Glaucoma 360 conference, co-founded by Adrienne Graves, PhD, and Andrew Iwach, MD, and hosted by Glaucoma Research Foundation, will be held from February 6-8, 2025, at the Westin St. Francis in San Francisco, California. The event will focus on the latest advancements in glaucoma care and encourage innovation and collaboration.

A team of Bascom Palmer Eye Institute and University of Miami researchers have received an award to fund the procurement, preservation, and transplantation of a human eye to restore vision.

Melt Pharmaceuticals announced positive results from its Phase 3 study of MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery. The results support a regulatory submission, with potential to revolutionize sedation practices in various medical specialties.

HelpMeSee’s Mazava Project trains general practitioners in Madagascar to perform cataract surgeries, addressing the country’s high rate of avoidable blindness. Trainees gain proficiency through simulation-based learning and live surgeries, improving access to eye care in remote areas.

Analysis highlights discrepancies between adult, pediatric cataract procedures.

The phase 3 trial was conducted by licensee, Grand Pharma in Chinese cataract surgery patients.

The investigators conducted a randomized controlled trial of 60 patients who underwent monitored anesthesia care sedation for oculoplastic procedures from August 2018 to November 2020.

Kamran Riaz, MD, discussed with the Eye Care Network a study on mitomycin intravascular chemoembolization for treating corneal neovascularization. The procedure showed promise, with a 70% success rate at 3 to 6 months, though patient selection is crucial. Some required multiple treatments, but overall outcomes are promising.

Custom-designed, lens-based surgery is a less interventional surgical option.

A Norwegian study demonstrates that transplant rates continue to drop over time

Marketed as Triesence, it is a preservative free synthetic corticosteroid that is approved by the FDA for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids.

Clobetasol is FDA-approved for the treatment of post-operative inflammation and pain following ocular surgery.

In a study, a team of Chinese researchers looked at the mechanisms behind the development of EI and explored effective treatment options.

The Gni instrument technology represents a significant innovation in ophthalmic surgery, particularly in cataract procedures, according to Gulani.

According to the company, the center, which officially opens on Thursday, September 26, will serve as a hub for hands-on training and education in lens-based vision correction.

The study, funded by the National Institutes of Health, supports no change to surgical technique for trichiasis management.

The new standard: Stabilizing keratoconus and improving vision.

Unlocking the potential of donor scleral tissue: Innovations and future applications.

Researchers from NYU Langone published a study reporting on the eye's functioning, without sight but offering hope for the future.

APP13007, according to the company, is the first product developed using Formosa’s proprietary APNT nanoparticle formulation platform.